Research Analysts Offer Predictions for FENC FY2026 Earnings

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Investment analysts at HC Wainwright increased their FY2026 EPS estimates for Fennec Pharmaceuticals in a research note issued to investors on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.66 for the year, up from their previous estimate of $0.63. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share.

A number of other analysts have also recently commented on FENC. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Monday, March 10th. Craig Hallum upped their price target on shares of Fennec Pharmaceuticals from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th.

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at $8.29 on Wednesday. Fennec Pharmaceuticals has a 1-year low of $3.96 and a 1-year high of $8.41. The company’s fifty day simple moving average is $6.01 and its 200-day simple moving average is $6.00. The stock has a market capitalization of $228.96 million, a PE ratio of -82.89 and a beta of 0.32.

Fennec Pharmaceuticals (NASDAQ:FENC) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. The firm had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $8.18 million. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%. During the same quarter in the prior year, the business earned $0.41 EPS.

Insider Activity

In other news, Director Rosty Raykov sold 10,000 shares of the stock in a transaction on Friday, April 4th. The shares were sold at an average price of $5.25, for a total value of $52,500.00. Following the sale, the director now owns 61,156 shares of the company’s stock, valued at approximately $321,069. This represents a 14.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jeffrey S. Hackman bought 13,965 shares of the firm’s stock in a transaction dated Monday, May 19th. The shares were acquired at an average price of $6.99 per share, with a total value of $97,615.35. Following the completion of the transaction, the chief executive officer now owns 15,000 shares of the company’s stock, valued at approximately $104,850. The trade was a 1,349.28% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 30,000 shares of company stock worth $183,500 over the last quarter. Insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Rosalind Advisors Inc. bought a new position in Fennec Pharmaceuticals in the fourth quarter worth about $7,962,000. AIGH Capital Management LLC acquired a new stake in Fennec Pharmaceuticals in the 1st quarter worth approximately $2,199,000. Solas Capital Management LLC grew its position in Fennec Pharmaceuticals by 17.0% during the 4th quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company’s stock worth $14,226,000 after purchasing an additional 327,383 shares during the last quarter. Clayton Partners LLC acquired a new stake in shares of Fennec Pharmaceuticals during the fourth quarter worth about $256,000. Finally, Nuveen LLC purchased a new stake in Fennec Pharmaceuticals in the first quarter valued at approximately $158,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.